India, May 20 -- Shares of NeurAxis, Inc. (NRXS) were surging around 170 percent in the pre-market activity on the NYSE after the medical technology announced Tuesday that it has received clearance from the U.S. Food and Drug Administration for IB-Stim for the treatment of Pediatric Functional Dyspepsia.
NeurAxis received FDA 510(k) clearance for IB-Stim to treat Pediatric Functional Abdominal Pain or FAP associated with Functional Dyspepsia, and FD related Nausea Symptoms, in patients aged 8 to 21 years.
According to the firm, the new indication represents the first treatment ever cleared or approved by the FDA related to functional dyspepsia. It is expected to nearly double the Company's total addressable market in non-invasive, pediatr...